NEEDHAM, Mass. — September 2, 2025 — Leads & Copy — Candel Therapeutics, Inc. (Candel) (Nasdaq: CADL) has appointed Carl H. June, M.D., to its Research Advisory Board (RAB). Dr. June, an expert in cancer immunotherapy and a pioneer in CAR-T cell therapy, will bring his expertise to Candel as it advances its viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 for recurrent high-grade glioma.
Dr. June expressed his enthusiasm for joining Candel’s Research Advisory Board, citing the company’s innovative approach to viral immunotherapy and its potential to help patients across multiple cancer types.
Dr. June is the Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania’s Perelman School of Medicine. He also directs the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. His research centers on lymphocyte activation mechanisms related to immune tolerance and adoptive immunotherapy for cancer and chronic infection.
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel, expressed excitement about Dr. June’s addition to the Research Advisory Board. Tak noted that June’s expertise in T cell engineering and immunology will be an invaluable resource as the company advances CAN-2409 across multiple solid tumors, with a Biologics License Application (BLA) submission for prostate cancer expected in Q4 2026.
Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing off-the-shelf, multimodal viral immunotherapies. Candel has established two clinical-stage multimodal biological immunotherapy platforms. CAN-2409 is the lead product candidate from the adenovirus platform.
Candel recently completed phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer. The FDA has granted Fast Track Designation to CAN-2409 plus prodrug (valacyclovir) for the treatment of PDAC, stage III/IV NSCLC, and localized primary prostate cancer in combination with radiation therapy. The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer and Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
CAN-3110 is the lead product candidate from the HSV platform and is currently in a phase 1b clinical trial in recurrent high-grade glioma. Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform to create new viral immunotherapies for solid tumors.
Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Source: Candel Therapeutics, Inc.
